Chronic obstructive pulmonary disease

AMC Health Launches CHF and COPD RPM Programs for Blue Cross & Blue Shield of Rhode Island to Help Medicare Advantage Members Manage Their Conditions at Home

Wednesday, May 12, 2021 - 1:33pm

b'NEW YORK, May 12, 2021 /PRNewswire/ -- AMC Health , the leading provider in telehealth and remote patient monitoring (RPM) technology and clinical services, today announced the launch of a Congestive Heart Failure (CHF) and Chronic Obstructive Pulmonary Disease (COPD) programs with Blue Cross & Blue Shield of Rhode Island (BCBSRI) for its Medicare Advantage members.

Key Points: 
  • b'NEW YORK, May 12, 2021 /PRNewswire/ -- AMC Health , the leading provider in telehealth and remote patient monitoring (RPM) technology and clinical services, today announced the launch of a Congestive Heart Failure (CHF) and Chronic Obstructive Pulmonary Disease (COPD) programs with Blue Cross & Blue Shield of Rhode Island (BCBSRI) for its Medicare Advantage members.
  • As millions are still sheltering at home due to COVID-19, AMC Health and BCBSRI are providing solutions to help participants stay connected to their providers and nurses.\nFor two-decades, AMC Health has led healthcare transformation through the use of virtual technologies.
  • AMC Health\'s peer-reviewed published studies highlight clinical improvements for conditions like heart failure, diabetes, and hypertension, resulting in reductions in hospital admissions, and solid financial return on investment.
  • For more information, visit www.amchealth.com .\nMedia Contact for AMC Health:\nView original content to download multimedia: http://www.prnewswire.com/news-releases/amc-health-launches-chf-and-copd...\n'

PAOG Confirms CBD Nutraceutical Q4 Revenue Plans

Tuesday, May 11, 2021 - 7:58pm

b'Sandusky, Ohio--(Newsfile Corp. - May 11, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today confirmed plans to introduce three CBD Nutraceutical Products beginning in the fourth quarter of this year, 2021.\nOn Friday, PAOG released a preview of the company\'s plan to launch a CBD Nutraceuticals line of products.

Key Points: 
  • b'Sandusky, Ohio--(Newsfile Corp. - May 11, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today confirmed plans to introduce three CBD Nutraceutical Products beginning in the fourth quarter of this year, 2021.\nOn Friday, PAOG released a preview of the company\'s plan to launch a CBD Nutraceuticals line of products.
  • PAOG\'s CBD Nutraceuticals are expected to generate revenue this year, in 2021, while the company continues with its long-term CBD pharmaceutical developments.\nPAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.
  • All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties.
  • Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above.

Monaghan Medical and Captis join forces to improve patient outcomes

Tuesday, May 11, 2021 - 1:45pm

b'PLATTSBURGH, N.Y., May 11, 2021 (GLOBE NEWSWIRE) -- Monaghan Medical Corporation (Monaghan) and Captis today announced their agreement to a three-year contract creating a partnership between two industry leaders.

Key Points: 
  • b'PLATTSBURGH, N.Y., May 11, 2021 (GLOBE NEWSWIRE) -- Monaghan Medical Corporation (Monaghan) and Captis today announced their agreement to a three-year contract creating a partnership between two industry leaders.
  • Monaghan and its affiliates are leaders in the development, manufacture, and distribution of medical devices that improve the quality of life of patients with respiratory diseases like asthma, Cystic Fibrosis, and COPD.
  • They recognize that cost savings fully materialize when staff efficiencies, inventory consolidation, and patient outcomes all improve.
  • Captis is supported by two service providers, Mayo Clinic Supply Chain and Vizient Member Business Ventures.\n'

PAOG 2021 CBD Nutraceuticals Sales Plan Preview This Friday To Include ALKM and USMJ Partnership Highlights

Thursday, May 6, 2021 - 5:05pm

RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.

Key Points: 
  • RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.
  • There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.
  • Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above.
  • The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.\n'

PAOG 2021 CBD Nutraceuticals Rollout Preview This Friday

Wednesday, May 5, 2021 - 5:12pm

b'Sandusky, Ohio--(Newsfile Corp. - May 5, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today confirmed a CBD Nutraceutical Sales Rollout Presentation scheduled this Friday, May 7, 2021.\nLast year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).

Key Points: 
  • b'Sandusky, Ohio--(Newsfile Corp. - May 5, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today confirmed a CBD Nutraceutical Sales Rollout Presentation scheduled this Friday, May 7, 2021.\nLast year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).
  • RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.
  • 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.
  • The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.\n'

PAOG CBD Nutraceuticals to Hit Market This Year

Tuesday, May 4, 2021 - 1:59pm

b'Sandusky, Ohio--(Newsfile Corp. - May 4, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today confirmed plans to present the Company\'s CBD Nutraceutical Sales Rollout Plan this Friday, May 7, 2021.\nLast year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).

Key Points: 
  • b'Sandusky, Ohio--(Newsfile Corp. - May 4, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today confirmed plans to present the Company\'s CBD Nutraceutical Sales Rollout Plan this Friday, May 7, 2021.\nLast year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).
  • RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.
  • 9,199,960 entitled, "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.
  • The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.\n'

PAOG 2021 CBD Nutraceutical Sales Rollout Plan Presentation Scheduled This Friday

Monday, May 3, 2021 - 8:22pm

b'Sandusky, Ohio--(Newsfile Corp. - May 3, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today announced plans to present the company\'s CBD Nutraceutical Sales Rollout Plan this Friday, May 7, 2021.\nLast year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).

Key Points: 
  • b'Sandusky, Ohio--(Newsfile Corp. - May 3, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today announced plans to present the company\'s CBD Nutraceutical Sales Rollout Plan this Friday, May 7, 2021.\nLast year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).
  • RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.
  • 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.
  • The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.\n'

AI Cluster Modeling on COVID-19 Data at Scale Offers Opportunity for Improved Patient Outcomes

Friday, April 30, 2021 - 9:00pm

With access to historical patient data and sustained monitoring of potential "long-Covid" symptoms as they emerge, medical practitioners are able to rapidly identify patterns and optimize response.\nDr.

Key Points: 
  • With access to historical patient data and sustained monitoring of potential "long-Covid" symptoms as they emerge, medical practitioners are able to rapidly identify patterns and optimize response.\nDr.
  • Vafa Bayat, Bitscopic\'s Head of R&D, said: "By highlighting best practices specific to subpopulations, we can better personalize care.
  • For example, older patients tend to present with pre-existing chronic conditions such as congestive heart failure (CHF) and chronic obstructive pulmonary disease (COPD).
  • Bitscopic\'s Praedico platform integrates electronic health data from the VA\'s 160+ hospitals with 9 unique million patient records in near-real time, and translates this data into actionable insights and alerts.

Global COPD Disease Market Insights and Market Forecasts Report 2020-2026 - ResearchAndMarkets.com

Friday, April 30, 2021 - 9:23am

b'The "COPD - Disease Insights and Market Forecasts to 2026" report has been added to ResearchAndMarkets.com\'s offering.\n"COAD/COPD: Disease Insights and Market Forecasts to 2026" report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of COAD/COPD disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for COAD/COPD, drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2026.\nThis section of the report gives the overview of COAD/COPD disease indication in detail.

Key Points: 
  • b'The "COPD - Disease Insights and Market Forecasts to 2026" report has been added to ResearchAndMarkets.com\'s offering.\n"COAD/COPD: Disease Insights and Market Forecasts to 2026" report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of COAD/COPD disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for COAD/COPD, drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2026.\nThis section of the report gives the overview of COAD/COPD disease indication in detail.
  • The section highlights the basic definition, causes and symptoms of disease and details the types of COAD/COPD disease.
  • Further details on the profile of COAD/COPD patients, Symptoms experienced by the patients, and disease progression in patients are outlined in the report.
  • The report further highlights the multiple methods through which the patient can be diagnosed for COAD/COPD disease.\nThis section of the report provides the overview of COAD/COPD diagnosed prevalent and treated patients in the US, EU5 and Japan market year wise starting from 2018 till 2026.

Introducing the Portex® Acapella® Choice Blue Vibratory Positive Expiratory Pressure (PEP) Therapy System

Wednesday, April 28, 2021 - 4:59pm

b'Smiths Medical, a leading medical device manufacturer, today announces the launch of the acapella\xc2\xae choice blue vibratory PEP therapy system.

Key Points: 
  • b'Smiths Medical, a leading medical device manufacturer, today announces the launch of the acapella\xc2\xae choice blue vibratory PEP therapy system.
  • Impact of Oscillating Positive Expiratory Pressure Device Use on Post-Discharge Hospitalizations: A Retrospective Cohort Study Comparing Patients with COPD or Chronic Bronchitis Using the Aerobika\xc2\xae and Acapella\xc2\xae Devices.
  • Positive Expiratory Pressure Therapy with And Without Oscillation and Hospital Length of Stay for Acute Exacerbation of Chronic Obstructive Pulmonary Disease.
  • 2019 Nov 20;14:2553-2561.\nMesquita FO, Galindo-Filho VC, Neto JL, Galv\xc3\xa3o AM, Brand\xc3\xa3o SC, Fink JB, Dornelas-de-Andrade A. Scintigraphic assessment of radio-aerosol pulmonary deposition with the acapella positive expiratory pressure device and various nebulizer configurations.